EP0877795A4 - Isolement de cellules precurseurs a partir de tissus hematopoietiques et non hematopoietiques et leur utilisation - Google Patents

Isolement de cellules precurseurs a partir de tissus hematopoietiques et non hematopoietiques et leur utilisation

Info

Publication number
EP0877795A4
EP0877795A4 EP97903115A EP97903115A EP0877795A4 EP 0877795 A4 EP0877795 A4 EP 0877795A4 EP 97903115 A EP97903115 A EP 97903115A EP 97903115 A EP97903115 A EP 97903115A EP 0877795 A4 EP0877795 A4 EP 0877795A4
Authority
EP
European Patent Office
Prior art keywords
cells
tissue
bone
cell
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97903115A
Other languages
German (de)
English (en)
Other versions
EP0877795A1 (fr
Inventor
Dale R Peterson
Nancy Nousek-Goebl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DePuy Orthopaedics Inc
Original Assignee
DePuy Orthopaedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DePuy Orthopaedics Inc filed Critical DePuy Orthopaedics Inc
Publication of EP0877795A1 publication Critical patent/EP0877795A1/fr
Publication of EP0877795A4 publication Critical patent/EP0877795A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3821—Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3847—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3852—Cartilage, e.g. meniscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin

Definitions

  • the present invention generally relates to the
  • Osteogenesis and chondrogenesis are highly complex
  • chondrogenesis does not typically occur to repair
  • cartilage precursor cells from marrow cartilage precursor cells from marrow
  • bone marrow contained a restorative factor having the
  • bone marrow contains one or
  • stem cells More populations of pluripotent cells, known as stem cells.
  • T lymphocytes or more specialized cell types, such as T lymphocytes
  • stem cells are defined as precursor cells
  • MSC mesenchymal stem cells
  • MSC are a population of cells having the capacity to
  • cartilage including cartilage, bone, tendon, ligament, and other
  • mesenchymal tissue types apparently derive from a
  • MSC common progenitor stem cell
  • HSC Hematopoietic stem cells
  • SSC stromal stem cells
  • marrow i.e. hematopoietic, mesenchymal, and
  • human fetal bone marrow contains separate
  • Ly-6 antigens are also expressed by cells
  • hematopoietic systems is the cell surface antigen known
  • CD34 is expressed by about 1% to 5% of normal
  • CD34+ cells are a mixture of immature blastic cells and
  • CD34 is a marker for HSC and hematopoietic progenitor
  • CD34 is widely recognized as a marker for
  • marrow-derived mesenchymal cells are detected by
  • amplified, marrow-isolated MSC may then be introduced
  • mesenchymal cells are detected by monoclonal
  • the present invention provides a
  • tissue types including peripheral blood, marrow, and
  • the precursor cells are isolated using
  • CD34+ precursor cells for example CD33
  • CD38, CD74, and THYl are CD38, CD74, and THYl. Significantly, the present
  • precursor cells in further in vivo procedures. Indeed, precursor cells
  • the present invention relates to a
  • hematopoietic and non-hematopoietic tissues including
  • the method includes steps of
  • CD34 or other antigens on CD34+ precursor cells CD34 or other antigens on CD34+ precursor cells
  • Precursor cells isolated by the present method may be used immediately for bone and cartilage
  • the present invention is a method
  • the present mvention is a
  • the present invention is a
  • Adipose tissue is one of ' the most convenient sources of
  • adipose tissue is intended to mean fat and other
  • sources of microvascular tissue in the body such as
  • TGF- ⁇ growth factor
  • osteoblasts which have the capacity to promote bone
  • Pluripotent precursor cell having the ability to
  • the present invention is premised upon two
  • non-hematopoietic tissue sources including peripheral edge and peripheral edge
  • identifier for connective tissue precursor cells may be used as a marker for precursor cells having the
  • sources for precursor cells viz. peripheral blood and
  • present invention enables isolation of these cells from
  • osteogenic and chondrogenic precursor cells from
  • the present invention is an
  • CD33, CD38, CD74, and THYl which list is not intended
  • precursor cells are isolated from adipose tissue based on differential
  • isolating precursor cells involves collecting a body
  • tissue sample contacting the sample with an antibody
  • red cells Removal of red cells is not essential
  • Red cells may be removed from the
  • sample by any suitable means, for example, lysis,
  • the sample also be anticoagulated by,
  • treatment with citrate, heparin, or EDTA for example, treatment with citrate, heparin, or EDTA.
  • the yield of precursor cells is expected to be
  • Yields may vary, depending upon the health and
  • the yield may be dramatically increased by
  • precursor cells from peripheral blood involves contacting the blood sample with a reagent that
  • reagents include lectins, for example soy bean
  • mAb monoclonal or polyclonal antibodies may be used.
  • cell surface markers on CD34+ cells may be obtained
  • CD34 and other antigens on CD34+ cells include CD34 and other antigens on CD34+ cells, for
  • the antibody to enable binding, the precursor cell-
  • antibody complex is recovered by any suitable method
  • the affinity recovery method utilizes a
  • separation kit includes biotin-labeled human anti-CD34
  • the primary antibody could be directed against a precursor cell
  • biotin directed against the primary antibody.
  • the secondary antibody may be coupled to
  • Bone marrow is collected by any combination
  • an anticoagulant such as EDTA, heparin, or citrate
  • nucleated cells are separated from non-nucleated cells
  • antigen are isolated from marrow using a reagent that
  • Bound cells are separated from unbound cells by
  • affinity chromatography affinity chromatography, magnetic beads, or by panning.
  • an antibody directed to the preferred embodiment is an antibody directed to the preferred embodiment.
  • microvascular cells Microvascular tissue, from which
  • Microvascular tissue is composed of at least
  • endothelial cells pericytes, or both may be
  • osteoprecursor cells or alternatively, that
  • endothelial cells and pericytes increase proliferation
  • adipose tissue has two embodiments. In the first
  • the tissue is contacted with a reagent that
  • binding reagents for use with adipose tissue include
  • affinity binding method as applied to adipose tissue
  • suitable dissociation enzyme such as, for example,
  • collagenase may be used.
  • Cells that bind the reagent may be used.
  • fat could be secured by
  • the adipocytes are separated from
  • Adipocytes float to
  • harvested precursor cells they can be mixed with a
  • cells may be isolated from a variety of hematopoietic
  • non-hematopoietic body tissues such as peripheral hematopoietic body tissues
  • source may be implanted at any connective tissue site
  • implanting procedures include surgery or arthroscopic
  • precursor cells will differentiate into bone or cartilage if transplanted to a site in the body needing
  • the cells be mixed
  • proteins such as
  • polysaccharides polysaccharides, saccharides, methylcellulose, agar, or
  • proteoglycans algenate; proteoglycans; synthetic polymers; ceramics;
  • osteogenic precursor cells or growth factors
  • vascularization and cell migration can occur.
  • the present invention provides a source of
  • precursor cells are first mixed with a carrier material
  • the carrier insures that the
  • the model consisted of monitoring the ability of
  • bodyweights in the range of about 300 g to 500 g
  • test samples were mixed with a carrier
  • the positive control consisted of an autograft
  • TCP phosphate
  • the scoring criteria are
  • Rat bone marrow was isolated from the
  • Fisher rats between 8 to 10 weeks of age. Prior to
  • the marrow was extracted from
  • neat state consists of 2.2g Na3Citrate.2H20, 0.8g
  • the cells were washed in 5 ml of ACD and
  • albumin, phosphate buffered saline; supplied with CEPRATE LC kit) /All PBS was Ca+2 and Mg+2 free to
  • CD34+ cells labeled with mAb 2C6 or 5E6 were separated
  • kit "CEPRATE LC, " may be obtained from CellPro
  • Example 2 were resuspended in about 0.5 ml of
  • the column contained a bed
  • CD34+ cells at a purity of about 50%.
  • CD34+ cells were implanted into rat calvarial
  • Rat tail collagen is preferred, however, since
  • the cell pellet was washed twice in 10 ml
  • PBS Phosphate Buffered Saline
  • Red cells were lysed by mixing the whole blood with 300
  • step (a) was incubated with 3 ml of neat mAb 2C6
  • Antibody-bound cells were released from the column as
  • the washed pellet was mixed with 50 ml rat tail
  • 2C6 and 5E6 cells were isolated from marrow

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne la régénération osseuse et cartilagineuse au moyen de sous-ensembles cellulaires issus de tissus hématopoïétiques et non hématopoïétiques. On isole les cellules précurseurs des os et du cartilage dans le sang périphérique, la moelle osseuse et les tissus adipeux, en utilisant des anticorps et d'autres réactifs qui reconnaissent le marqueur superficiel CD34 des cellules hématopoïétiques et d'autres marqueurs sur les cellules CD34+. Ces cellules précurseurs, peuvent être utilisées pour la régénération osseuse ou cartilagineuse in vivo, par transplantation, avec ou sans matériau transporteur, dans des sites à l'intérieur du corps nécessitant une réparation osseuse ou cartilagineuse, et ce, sans qu'il y ait besoin de mise en culture in vitro. De telles cellules précurseurs peuvent également s'utiliser pour l'ensemencement de dispositifs prothétiques afin d'accroître l'aptitude à l'implantation.
EP97903115A 1996-01-16 1997-01-13 Isolement de cellules precurseurs a partir de tissus hematopoietiques et non hematopoietiques et leur utilisation Withdrawn EP0877795A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58731596A 1996-01-16 1996-01-16
US587315 1996-01-16
PCT/US1997/001213 WO1997026326A1 (fr) 1996-01-16 1997-01-13 Isolement de cellules precurseurs a partir de tissus hematopoietiques et non hematopoietiques et leur utilisation

Publications (2)

Publication Number Publication Date
EP0877795A1 EP0877795A1 (fr) 1998-11-18
EP0877795A4 true EP0877795A4 (fr) 2003-03-05

Family

ID=24349303

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97903115A Withdrawn EP0877795A4 (fr) 1996-01-16 1997-01-13 Isolement de cellules precurseurs a partir de tissus hematopoietiques et non hematopoietiques et leur utilisation

Country Status (3)

Country Link
EP (1) EP0877795A4 (fr)
JP (1) JP2000503542A (fr)
WO (1) WO1997026326A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200606B1 (en) * 1996-01-16 2001-03-13 Depuy Orthopaedics, Inc. Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration
CA2198978A1 (fr) * 1996-03-01 1997-09-01 Clemens Antoni Van Blitterswijk Methode pour la production d'os in vitro
FR2771102B1 (fr) * 1997-11-14 2000-12-15 Biocoral Inc Procede pour induire la differenciation osteoblastique de cellules de tissu adipeux extramedullaire humain
EP1016413A1 (fr) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Hormone de croissance humaine (HGH) pour stimuler la mobilisation de cellules souches hematopoietiques pluripotentes
BR0008552A (pt) * 1999-03-10 2002-05-07 Univ Pittsburgh Células tronco e redes derivadas de tecido adiposo
US20030082152A1 (en) 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
US20050076396A1 (en) * 1999-03-10 2005-04-07 Katz Adam J. Adipose-derived stem cells and lattices
DE60023474T2 (de) 1999-03-30 2006-06-29 Netech Inc., Kawasaki Methode zur selektiven trennung von blutzellen unter verwendung von lektin
ES2230157T3 (es) 1999-10-06 2005-05-01 Tigenix N.V. Aislamiento de celulas precursoras y su uso para la reparacion de tejidos.
FR2819265B1 (fr) * 2001-01-10 2004-01-02 Centre Nat Rech Scient Cellules du tissu adipeux extramedullaire et leurs applications dans la reconstitution des lignees hematopoietiques
US7585670B2 (en) 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US7651684B2 (en) 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
US20050048035A1 (en) 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
JP4653952B2 (ja) 2001-12-07 2011-03-16 サイトリ セラピューティクス インコーポレイテッド 処理済み脂肪吸引細胞で患者を治療するためのシステムと方法
US7514075B2 (en) 2001-12-07 2009-04-07 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating adipose derived stem cells from tissue
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US7595043B2 (en) 2001-12-07 2009-09-29 Cytori Therapeutics, Inc. Method for processing and using adipose-derived stem cells
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US7291450B2 (en) * 2003-03-28 2007-11-06 Smith & Nephew, Inc. Preparation of a cell concentrate from a physiological solution
JP2006122017A (ja) * 2004-11-01 2006-05-18 Toyama Prefecture 磁気スポットアレイチップを用いる細胞の回収方法
KR100833793B1 (ko) * 2006-05-16 2008-05-29 세원셀론텍(주) 골수 유래 골 생성용 유핵 세포 분리 방법
JP5515133B2 (ja) * 2007-10-24 2014-06-11 株式会社カネカ 骨再生組成物製造器具
KR20100007180A (ko) * 2008-07-11 2010-01-22 세원셀론텍(주) 뼈 재생용 콜라겐 젤 조성물의 제조방법
WO2010021993A1 (fr) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Procédés d'utilisation de cellules issues du tissu adipeux dans le traitement du système lymphatique et d'une maladie maligne
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
KR101738324B1 (ko) 2009-05-01 2017-05-19 비미니 테크놀로지스 엘엘씨 조직 및 세포 부유화 이식편의 최적화 시스템, 방법 및 조성물
US20140286911A1 (en) 2013-03-15 2014-09-25 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
SG191206A1 (en) * 2010-12-17 2013-07-31 Cell Ideas Pty Ltd Arthroscopy method
US9044430B2 (en) 2011-03-18 2015-06-02 Microvascular Tissues, Inc. Allogeneic microvascular tissue for soft tissue treatments
US11819522B2 (en) 2012-09-19 2023-11-21 Microvascular Tissues, Inc. Compositions and methods for treating and preventing tissue injury and disease
US10596202B2 (en) 2012-09-19 2020-03-24 Microvascular Tissues, Inc. Compositions and methods for treating and preventing tissue injury and disease
US9872937B2 (en) 2012-09-19 2018-01-23 Microvascular Tissues, Inc. Compositions and methods for treating and preventing tissue injury and disease
ES2710921T3 (es) 2012-09-19 2019-04-29 Microvascular Tissues Inc Composiciones para tratar y prevenir lesión y enfermedad tisular

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451611A2 (fr) * 1990-03-30 1991-10-16 Sandoz Ltd Cellules de souche hématopoiétiques humaines
WO1996005290A1 (fr) * 1994-08-12 1996-02-22 The Regents Of The University Of Michigan Cellules osseuses precurseurs: compositions et methodes
WO1996040875A1 (fr) * 1995-06-07 1996-12-19 Novartis Ag Procedes d'obtention de compositions enrichies en cellules souches hematopoietiques et anticorps utilises a cet effet

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281422A (en) * 1991-09-24 1994-01-25 Purdue Research Foundation Graft for promoting autogenous tissue growth
CA2122141C (fr) * 1991-10-23 2007-07-17 Shelly Heimfeld Methode de multiplication selective de cellules souches

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451611A2 (fr) * 1990-03-30 1991-10-16 Sandoz Ltd Cellules de souche hématopoiétiques humaines
WO1996005290A1 (fr) * 1994-08-12 1996-02-22 The Regents Of The University Of Michigan Cellules osseuses precurseurs: compositions et methodes
WO1996040875A1 (fr) * 1995-06-07 1996-12-19 Novartis Ag Procedes d'obtention de compositions enrichies en cellules souches hematopoietiques et anticorps utilises a cet effet

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BJOERNTORP P ET AL: "ISOLATION AND CHARACTERIZATION OF CELLS FROM RAT ADIPOSE TISSUE DEVELOPING INTO ADIPOCYTES", JOURNAL OF LIPID RESEARCH, BETHESDA, MD, US, vol. 19, no. 3, 1978, pages 316 - 324, XP000613823, ISSN: 0022-2275 *
BRUDER S P ET AL: "MESENCHYMAL STEM CELLS IN BONE DEVELOPMENT, BONE REPAIR, AND SKELETAL REGENERATION THERAPY", JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, NEW YORK, US, US, vol. 56, no. 3, 1994, pages 283 - 294, XP000865959, ISSN: 0021-9525 *
DE WYNTER E.A. ET AL: "Comparison of purity and enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral blood (primed for apheresis) using five separation systems.", STEM CELLS, vol. 13, 1995, pages 524 - 532, XP002936689 *
GRONTHOS S ET AL: "THE STRO-1+ FRACTION OF ADULT HUMAN BONE MARROW CONTAINS THE OSTEOGENIC PRECURSORS", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 84, no. 12, 15 December 1994 (1994-12-15), pages 4164 - 4173, XP000616142, ISSN: 0006-4971 *
MARGEL S ET AL: "CELL FRACTIONATION WITH AFFINITY LIGANDS CONJUGATED TO AGAROSE-POLYACROLEIN MICROSPHERE BEADS", JOURNAL OF CELL SCIENCE, ESSEX, GB, no. 62, July 1983 (1983-07-01), pages 149 - 159, XP001070920 *
MARKO O ET AL: "ISOLATION OF A PREADIPOCYTE CELL LINE FROM RAT BONE MARROW AND DIFFERENTIATION TO ADIPOCYTES", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 136, no. 10, 1995, pages 4582 - 4588, XP002929796, ISSN: 0013-7227 *
PEREIRA M E A ET AL: "IMMUNOCHEMICAL STUDIES ON LECTINS AND THEIR APPLICATION TO THE FRACTIONATION OF BLOOD GROUP SUBSTANCES AND CELLS", CRITICAL REVIEWS IN IMMUNOLOGY, CRC PRESS, INC, XX, vol. 1, no. 1, November 1979 (1979-11-01), pages 33 - 78, XP001070927, ISSN: 1040-8401 *
RICKARD D J ET AL: "ISOLATION AND CHARACTERIZATION OF OSTEOBLAST PRECURSOR CELLS FROM HUMAN BONE MARROW", MOLECULAR AND GENERAL GENETICS, SPRINGER VERLAG, BERLIN,, DE, vol. 11, no. 3, 1996, pages 312 - 324, XP002919287, ISSN: 0026-8925 *
See also references of WO9726326A1 *
SIMMONS P.J. ET AL.: "Isolation, characterization and functional activity of human marrow stromal progenitors in hemopoiesis.", PROGRESS IN CLINICAL AND BIOLOGICAL RESEARCH, vol. 389, 1994, pages 271 - 280, XP001097303 *
WALLER E K ET AL: "THE COMMON STEM CELL HYPOTHESIS REEVALUATED: HUMAN FETAL BONE MARROW CONTAINS SEPARATE POPULATIONS OF HEMATOPOIETIC AND STROMAL PROGENITORS", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 85, no. 9, 1 May 1995 (1995-05-01), pages 2422 - 2435, XP000929998, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO1997026326A1 (fr) 1997-07-24
JP2000503542A (ja) 2000-03-28
EP0877795A1 (fr) 1998-11-18

Similar Documents

Publication Publication Date Title
US6200606B1 (en) Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration
EP0877795A1 (fr) Isolement de cellules precurseurs a partir de tissus hematopoietiques et non hematopoietiques et leur utilisation
US5965436A (en) Method of isolating mesenchymal stem cells associated with isolated megakaryocytes by isolating megakaryocytes
US6387367B1 (en) Human mesenchymal stem cells
CA2583151C (fr) Identification et isolement de cellules multipotentes issues du tissu mesenchymateux non osteochondral
KR100489248B1 (ko) 제대혈 유래 간엽줄기세포ㆍ전구세포의 분리배양방법 및간엽조직으로의 분화유도방법
Kramer et al. In vivo matrix-guided human mesenchymal stem cells
WO1998020731A9 (fr) Compositions mixtes de cellules msc et de precurseurs de megacaryocytes et procede pour isoler les cellules msc associees aux megacaryocytes, en separant les megacaryocytes
KR101704072B1 (ko) 골 치유를 위한 조직 유래된 줄기 세포와 결합된 동종이식편
Gronthos et al. Isolation, purification and in vitro manipulation of human bone marrow stromal precursor cells
AU2011253985C1 (en) Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue
HK1236998A1 (en) Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980806

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 5/00 A, 7C 12N 15/00 B, 7A 61K 48/00 B, 7C 12N 5/06 B, 7A 61L 27/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20030121

17Q First examination report despatched

Effective date: 20030912

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040929